Market Eyes LiveIdexx Laboratories Inc (IDXX) Stock Rating & Analysis
MELANY's data-driven read on Idexx Laboratories Inc · in Vitro & in Vivo Diagnostic Substances.
Idexx Laboratories develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its main product lines include single-use canine and feline in-office test kits, benchtop chemistry and hematology analyzers for on-site test-panel analysis, reference lab services, and livestock disease tests. It also provides veterinary practice management software and consulting. Roughly 35% of its revenue comes from outside the US.
Why IDXX scores 52/100
MELANY scores Idexx Laboratories Inc 52/100 by weighing eight factors. Here is how IDXX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 62%
- ROE 74%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
What Wall Street price targets and revisions are signalling.
- Analyst targets 26% upside
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for IDXX
- Weak price momentum, trend not yet confirmed, may need more time to set up
Sector and theme context
Idexx Laboratories Inc sits in the Healthcare sector theme, which MELANY currently rates 54/100 for strength. Theme strength feeds IDXX's momentum and catalyst factors above.
Tracking IDXX
Idexx Laboratories Inc rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add IDXX to your watchlist and get alerted the moment the rating changes.
How MELANY rates IDXX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Idexx Laboratories Inc's 52/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about IDXX
Is Idexx Laboratories Inc (IDXX) a buy?
As of 2026-08-25, MELANY rated Idexx Laboratories Inc Hold with a composite score of 52/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Idexx Laboratories Inc's MELANY score?
Idexx Laboratories Inc (IDXX) has a MELANY composite score of 52/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the IDXX stock rating calculated?
MELANY scores IDXX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Idexx Laboratories Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Idexx Laboratories Inc (IDXX) Hold with a composite of 52/100 as of 2026-08-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the IDXX stock price forecast?
MELANY does not publish price targets or forecasts for IDXX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 52/100 across eight factors for Idexx Laboratories Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is IDXX stock overvalued or undervalued?
MELANY's valuation factor currently reads 17/100 for Idexx Laboratories Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives IDXX's read.
What price should I buy IDXX at?
MELANY is not flagging a fresh entry for IDXX at its current Hold rating, so there is no entry zone to publish right now. Watchlisting IDXX in the free app gets you alerted the moment that changes.
What are the risks of buying IDXX stock?
The top risks MELANY currently flags for Idexx Laboratories Inc: Weak price momentum, trend not yet confirmed, may need more time to set up. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Idexx Laboratories Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 90/100 for Idexx Laboratories Inc, and earnings track record, at 78/100. The 52/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will IDXX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 33/100 for IDXX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this IDXX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores IDXX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
IDXX's live rating and alerts are free either way. The app is our flagship.